FDA 21 CFR Part 11 vs 23 NYCRR 500
FDA 21 CFR Part 11
FDA regulation equating electronic records to paper equivalents
23 NYCRR 500
NY regulation for financial services cybersecurity
Quick Verdict
FDA 21 CFR Part 11 ensures electronic records/signatures trust for life sciences, while 23 NYCRR 500 mandates broad cybersecurity for NY financial firms. Pharma adopts Part 11 for FDA compliance; banks use 500 to avoid DFS fines and protect NPI.
FDA 21 CFR Part 11
21 CFR Part 11 Electronic Records; Electronic Signatures
Key Features
- Establishes electronic records/signatures equivalent to paper/handwritten
- Mandates secure, time-stamped audit trails for changes
- Requires unique, non-repudiable electronic signatures with manifestation
- Differentiates controls for closed vs. open systems
- Enforces validation, access limits, and authority checks
23 NYCRR 500
23 NYCRR Part 500 Cybersecurity Regulation
Key Features
- Annual CEO/CISO dual compliance certification
- 72-hour cybersecurity incident notification to NYDFS
- Mandated MFA for all information system access
- Risk-based TPSP security policy and contracts
- Annual penetration testing and vulnerability management
Detailed Analysis
A comprehensive look at the specific requirements, scope, and impact of each standard.
FDA 21 CFR Part 11 Details
What It Is
FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. The risk-based approach narrows scope to relied-upon electronic records, with enforcement discretion for validation, audit trails, retention, and copies per 2003 guidance.
Key Components
- **Subpart BControls for closed (§11.10) and open (§11.30) systems, including validation, audit trails, access limits, checks, signatures manifestation/linking.
- **Subpart CElectronic signature requirements (§§11.50-11.300) for uniqueness, multi-component controls, non-repudiation.
- Core principles: authenticity, integrity, confidentiality, accountability. No fixed control count; focuses on 11+ key controls like training, policies.
- Compliance via self-assessment, FDA inspection; no third-party certification.
Why Organizations Use It
Mandated for life sciences using electronic records; ensures data integrity for inspections, avoids warning letters. Benefits: inspection readiness, quality decisions, efficiency. Builds trust, reduces recalls, supports digital transformation.
Implementation Overview
Risk-based: scope records, classify systems, validate (CSV/IQ/OQ/PQ), implement controls, train, SOPs. Applies to pharma, devices, biotech; phased (6-24+ months). FDA audits via inspections.
23 NYCRR 500 Details
What It Is
23 NYCRR Part 500 is the New York Department of Financial Services (NYDFS) Cybersecurity Regulation, a prescriptive state-level mandate for financial services entities. It establishes minimum risk-based cybersecurity requirements to protect nonpublic information (NPI) and ensure operational integrity, applying to Covered Entities like banks, insurers, and mortgage firms licensed in New York.
Key Components
- 14 core requirements including cybersecurity program, CISO governance, MFA, encryption, TPSP oversight, penetration testing, and 72-hour incident reporting.
- Risk-based approach with annual assessments, dual CEO/CISO certification by April 15, and five-year record retention.
- Enhanced rules for Class A Companies (e.g., >$20M NY revenue, >2,000 employees) like independent audits and EDR.
Why Organizations Use It
- Mandatory compliance avoids multimillion-dollar fines (e.g., Robinhood $30M).
- Reduces cyber risk, improves resilience, and builds stakeholder trust.
- Aligns with enterprise risk management for competitive edge.
Implementation Overview
- Phased roadmap: gap analysis, asset inventory, MFA rollout, TPSP contracts, testing.
- Applies to NY-licensed financial entities; no third-party certification but annual compliance filing and DFS examinations.
Key Differences
| Aspect | FDA 21 CFR Part 11 | 23 NYCRR 500 |
|---|---|---|
| Scope | Electronic records/signatures trustworthiness | Broad cybersecurity program and NPI protection |
| Industry | Life sciences, pharma, medical devices (US) | NY financial services entities (state-specific) |
| Nature | Mandatory FDA regulation with enforcement discretion | Mandatory state regulation with active enforcement |
| Testing | Risk-based system validation (IQ/OQ/PQ) | Annual pen testing, bi-annual vulnerability scans |
| Penalties | Warning letters, product holds, CGMP violations | Multi-million fines, consent orders, license actions |
Scope
Industry
Nature
Testing
Penalties
Frequently Asked Questions
Common questions about FDA 21 CFR Part 11 and 23 NYCRR 500
FDA 21 CFR Part 11 FAQ
23 NYCRR 500 FAQ
You Might also be Interested in These Articles...
SOC 2 Trust Services Criteria in Plain English: Side-by-Side Decoder for Security, Availability, and Beyond
Decode AICPA Trust Services Criteria from auditor jargon to plain English with side-by-side tables, analogies & TL;DRs. CISOs & founders: implement SOC 2 contro
ISO 27701 2025 Update: Navigating Standalone Certification Myths, Audit Realities, and a 90-Day PIMS Launch Plan
Debunk ISO 27701 2025 standalone certification myths vs ISO 27001. Get a 90-day PIMS launch roadmap, checklists & audit prep to certify faster amid global priva
The 'Black Box' Risk: Why Human-in-the-Loop is the Ultimate Fail-Safe for 2026 Security Operations
Uncover the black box AI risk in security ops. Learn why human-in-the-loop auditing is crucial for 2026. Upskill analysts to ensure data privacy and robust secu
Run Maturity Assessments with GRADUM
Transform your compliance journey with our AI-powered assessment platform
Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.
Explore More Comparisons
See how FDA 21 CFR Part 11 and 23 NYCRR 500 compare against other standards